Antibody-dependent enhancement of severe dengue disease in humans
暂无分享,去创建一个
M. Halloran | E. Harris | L. Katzelnick | L. Gresh | J. Mercado | G. Kuan | A. Gordon | Á. Balmaseda | A. Balmaseda | M. Halloran | M. E. Halloran
[1] L. Reed,et al. A SIMPLE METHOD OF ESTIMATING FIFTY PER CENT ENDPOINTS , 1938 .
[2] Techniques for hemagglutination and hemagglutination-inhibition with arthropod-borne viruses. , 1958, The American journal of tropical medicine and hygiene.
[3] O. Lucas Adetokunho,et al. Special Programme for Research and Training in Tropical Diseases (TDR) TDR- FINAL REPORT SERIES , 2001 .
[4] J. Dalrymple,et al. Identification of distinct antigenic determinants on dengue-2 virus using monoclonal antibodies. , 1982, The American journal of tropical medicine and hygiene.
[5] M. K. Gentry,et al. Dengue virus-specific and flavivirus group determinants identified with monoclonal antibodies by indirect immunofluorescence. , 1982, The American journal of tropical medicine and hygiene.
[6] S. Halstead,et al. Risk factors in dengue shock syndrome: a prospective epidemiologic study in Rayong, Thailand. I. The 1980 outbreak. , 1984, American journal of epidemiology.
[7] G. Kuno,et al. Detecting artificial anti-dengue IgM immune complexes using an enzyme-linked immunosorbent assay. , 1987, The American journal of tropical medicine and hygiene.
[8] A. Nisalak,et al. Evidence that maternal dengue antibodies are important in the development of dengue hemorrhagic fever in infants. , 1988, The American journal of tropical medicine and hygiene.
[9] Use of an inhibition method of ELISA in the serologic diagnosis of dengue. Preliminary report , 1989 .
[10] A. Nisalak,et al. Antibody-dependent enhancement of dengue virus growth in human monocytes as a risk factor for dengue hemorrhagic fever. , 1989, The American journal of tropical medicine and hygiene.
[11] S. Vázquez,et al. Serological diagnosis of dengue by an ELISA inhibition method (EIM). , 1990, Memorias do Instituto Oswaldo Cruz.
[12] R. Lanciotti,et al. Rapid detection and typing of dengue viruses from clinical samples by using reverse transcriptase-polymerase chain reaction , 1992, Journal of clinical microbiology.
[13] P. Grambsch,et al. A Package for Survival Analysis in S , 1994 .
[14] N. Ferguson,et al. The effect of antibody-dependent enhancement on the transmission dynamics and persistence of multiple-strain pathogens. , 1999, Proceedings of the National Academy of Sciences of the United States of America.
[15] E. Harris,et al. Application of molecular typing techniques in the 1998 dengue epidemic in Nicaragua. , 1999, The American journal of tropical medicine and hygiene.
[16] G. Crane. Dengue haemorrhagic fever: diagnosis, treatment, prevention and control , 1999 .
[17] E. Harris,et al. Clinical, epidemiologic, and virologic features of dengue in the 1998 epidemic in Nicaragua. , 2000, The American journal of tropical medicine and hygiene.
[18] A. Nisalak,et al. Dengue viremia titer, antibody response pattern, and virus serotype correlate with disease severity. , 2000, The Journal of infectious diseases.
[19] A. Nisalak,et al. High circulating levels of the dengue virus nonstructural protein NS1 early in dengue illness correlate with the development of dengue hemorrhagic fever. , 2002, The Journal of infectious diseases.
[20] N. White,et al. Susceptibility to dengue hemorrhagic fever in vietnam: evidence of an association with variation in the vitamin d receptor and Fc gamma receptor IIa genes. , 2002, The American journal of tropical medicine and hygiene.
[21] M. Guzmán,et al. Diagnosis of Dengue Virus Infection by Detection of Specific Immunoglobulin M (IgM) and IgA Antibodies in Serum and Saliva , 2003, Clinical Diagnostic Laboratory Immunology.
[22] A. Nisalak,et al. Dengue Virus (DV) enhancing antibody activity in preillness plasma does not predict subsequent disease severity or viremia in secondary DV infection. , 2005, The Journal of infectious diseases.
[23] Ira B Schwartz,et al. Dynamic effects of antibody-dependent enhancement on the fitness of viruses. , 2005, Proceedings of the National Academy of Sciences of the United States of America.
[24] E. Harris,et al. Differences in dengue severity in infants, children, and adults in a 3-year hospital-based study in Nicaragua. , 2005, The American journal of tropical medicine and hygiene.
[25] Pejman Rohani,et al. Ecological and immunological determinants of dengue epidemics. , 2006, Proceedings of the National Academy of Sciences of the United States of America.
[26] E. Harris,et al. High seroprevalence of antibodies against dengue virus in a prospective study of schoolchildren in Managua, Nicaragua , 2006, Tropical medicine & international health : TM & IH.
[27] J. Farrar,et al. Maternal antibody and viral factors in the pathogenesis of dengue virus in infants. , 2007, The Journal of infectious diseases.
[28] J. Farrar,et al. Dengue in Vietnamese infants--results of infection-enhancement assays correlate with age-related disease epidemiology, and cellular immune responses correlate with disease severity. , 2008, The Journal of infectious diseases.
[29] E. Harris,et al. Evaluation of immunological markers in serum, filter-paper blood spots, and saliva for dengue diagnosis and epidemiological studies. , 2008, Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology.
[30] E. Harris,et al. The Nicaraguan Pediatric Dengue Cohort Study: Study Design, Methods, Use of Information Technology, and Extension to Other Infectious Diseases , 2009, American journal of epidemiology.
[31] A. Nisalak,et al. Dengue plaque reduction neutralization test (PRNT) in primary and secondary dengue virus infections: How alterations in assay conditions impact performance. , 2009, The American journal of tropical medicine and hygiene.
[32] E. Harris,et al. Tropism of dengue virus in mice and humans defined by viral nonstructural protein 3-specific immunostaining. , 2009, The American journal of tropical medicine and hygiene.
[33] R. Jarman,et al. A Prospective Nested Case-Control Study of Dengue in Infants: Rethinking and Refining the Antibody-Dependent Enhancement Dengue Hemorrhagic Fever Model , 2009, PLoS medicine.
[34] Cameron P Simmons,et al. Dengue virus infections and maternal antibody decay in a prospective birth cohort study of Vietnamese infants. , 2009, The Journal of infectious diseases.
[35] E. Harris,et al. Improvement in hospital indicators after changes in dengue case management in Nicaragua. , 2009, The American journal of tropical medicine and hygiene.
[36] Juan Carlos Albarracín Matute,et al. Index cluster study of dengue virus infection in Nicaragua. , 2010, The American journal of tropical medicine and hygiene.
[37] Cameron P Simmons,et al. The human immune response to Dengue virus is dominated by highly cross-reactive antibodies endowed with neutralizing and enhancing activity. , 2010, Cell host & microbe.
[38] Rosanna W. Peeling,et al. Dengue: a continuing global threat , 2010, Nature Reviews Microbiology.
[39] R. Rico-Hesse,et al. Structure and Function Analysis of Therapeutic Monoclonal Antibodies against Dengue Virus Type 2 , 2010, Journal of Virology.
[40] Angel Balmaseda,et al. High Dengue Case Capture Rate in Four Years of a Cohort Study in Nicaragua Compared to National Surveillance Data , 2010, PLoS neglected tropical diseases.
[41] Dana A. Focks,et al. Epidemiology of Dengue Virus in Iquitos, Peru 1999 to 2005: Interepidemic and Epidemic Patterns of Transmission , 2010, PLoS neglected tropical diseases.
[42] M. Guzmán,et al. Asymptomatic dengue infection in a Cuban population confirms the protective role of the RR variant of the FcgammaRIIa polymorphism. , 2010, The American journal of tropical medicine and hygiene.
[43] Tyler R. Prestwood,et al. Enhanced infection of liver sinusoidal endothelial cells in a mouse model of antibody-induced severe dengue disease. , 2010, Cell host & microbe.
[44] Juan Carlos Albarracín Matute,et al. Trends in patterns of dengue transmission over 4 years in a pediatric cohort study in Nicaragua. , 2010, The Journal of infectious diseases.
[45] Prida Malasit,et al. Cross-Reacting Antibodies Enhance Dengue Virus Infection in Humans , 2010, Science.
[46] E. Harris,et al. Evaluation of the Traditional and Revised WHO Classifications of Dengue Disease Severity , 2011, PLoS neglected tropical diseases.
[47] Cameron P. Simmons,et al. Kinetics of Viremia and NS1 Antigenemia Are Shaped by Immune Status and Virus Serotype in Adults with Dengue , 2011, PLoS neglected tropical diseases.
[48] N. Lennon,et al. Dynamics of Dengue Disease Severity Determined by the Interplay Between Viral Genetics and Serotype-Specific Immunity , 2011, Science Translational Medicine.
[49] Pradeep Kota,et al. Automated minimization of steric clashes in protein structures , 2011, Proteins.
[50] E. Harris,et al. Unusual Dengue Virus 3 Epidemic in Nicaragua, 2009 , 2011, PLoS neglected tropical diseases.
[51] Richard G. Jarman,et al. Determinants of Inapparent and Symptomatic Dengue Infection in a Prospective Study of Primary School Children in Kamphaeng Phet, Thailand , 2011, PLoS neglected tropical diseases.
[52] J. Crowe,et al. Persistence of Circulating Memory B Cell Clones with Potential for Dengue Virus Disease Enhancement for Decades following Infection , 2011, Journal of Virology.
[53] T. Hien,et al. Multicentre prospective study on dengue classification in four South‐east Asian and three Latin American countries , 2011, Tropical medicine & international health : TM & IH.
[54] Michael S. Diamond,et al. Structural Basis of Differential Neutralization of DENV-1 Genotypes by an Antibody that Recognizes a Cryptic Epitope , 2012, PLoS pathogens.
[55] D. Relman,et al. Temporal Dynamics of the Transcriptional Response to Dengue Virus Infection in Nicaraguan Children , 2012, PLoS neglected tropical diseases.
[56] P. Gilbert,et al. Nomenclature for immune correlates of protection after vaccination. , 2012, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[57] Amy C. Morrison,et al. Underrecognized mildly symptomatic viremic dengue virus infections in rural Thai schools and villages. , 2012, The Journal of infectious diseases.
[58] Angel Balmaseda,et al. Dominant Cross-Reactive B Cell Response during Secondary Acute Dengue Virus Infection in Humans , 2012, PLoS neglected tropical diseases.
[59] L. Coudeville,et al. Modelling the long-term persistence of neutralizing antibody in adults after one dose of live attenuated Japanese encephalitis chimeric virus vaccine. , 2012, Vaccine.
[60] Scott D Boyd,et al. Convergent antibody signatures in human dengue. , 2013, Cell host & microbe.
[61] M. Beltramello,et al. Therapeutic Efficacy of Antibodies Lacking FcγR against Lethal Dengue Virus Infection Is Due to Neutralizing Potency and Blocking of Enhancing Antibodies , 2013, PLoS pathogens.
[62] John S. Brownstein,et al. The global distribution and burden of dengue , 2013, Nature.
[63] E. Cromwell,et al. Correlation between Dengue-Specific Neutralizing Antibodies and Serum Avidity in Primary and Secondary Dengue Virus 3 Natural Infections in Humans , 2013, PLoS neglected tropical diseases.
[64] Edward C. Holmes,et al. Host and viral features of human dengue cases shape the population of infected and infectious Aedes aegypti mosquitoes , 2013, Proceedings of the National Academy of Sciences.
[65] E. Harris,et al. Symptomatic Versus Inapparent Outcome in Repeat Dengue Virus Infections Is Influenced by the Time Interval between Infections and Study Year , 2013, PLoS neglected tropical diseases.
[66] Soila Sukupolvi-Petty,et al. The Potent and Broadly Neutralizing Human Dengue Virus-Specific Monoclonal Antibody 1C19 Reveals a Unique Cross-Reactive Epitope on the bc Loop of Domain II of the Envelope Protein , 2013, mBio.
[67] Carmen Cadarso-Suárez,et al. smoothHR: An R Package for Pointwise Nonparametric Estimation of Hazard Ratio Curves of Continuous Predictors , 2013, Comput. Math. Methods Medicine.
[68] E. Harris,et al. The Nicaraguan Pediatric Dengue Cohort Study: Incidence of Inapparent and Symptomatic Dengue Virus Infections, 2004–2010 , 2013, PLoS neglected tropical diseases.
[69] E. Harris,et al. Analysis of Cross-Reactive Antibodies Recognizing the Fusion Loop of Envelope Protein and Correlation with Neutralizing Antibody Titers in Nicaraguan Dengue Cases , 2013, PLoS neglected tropical diseases.
[70] Pejman Rohani,et al. Interactions between serotypes of dengue highlight epidemiological impact of cross-immunity , 2013, Journal of The Royal Society Interface.
[71] Correction: Therapeutic Efficacy of Antibodies Lacking Fc. Receptor Binding against Lethal Dengue Virus Infection Is Due to Neutralizing Potency and Blocking of Enhancing Antibodies , 2013, PLoS Pathogens.
[72] T. Scott,et al. Dengue Virus Neutralizing Antibody Levels Associated with Protection from Infection in Thai Cluster Studies , 2014, PLoS neglected tropical diseases.
[73] Bhumi P. Patel,et al. Dengue Viruses Are Enhanced by Distinct Populations of Serotype Cross-Reactive Antibodies in Human Immune Sera , 2014, PLoS pathogens.
[74] D. Bates,et al. Fitting Linear Mixed-Effects Models Using lme4 , 2014, 1406.5823.
[75] Aaron A. King,et al. Time-varying, serotype-specific force of infection of dengue virus , 2014, Proceedings of the National Academy of Sciences.
[76] E. Harris,et al. A potent anti-dengue human antibody preferentially recognizes the conformation of E protein monomers assembled on the virus surface , 2014, EMBO molecular medicine.
[77] D. Cummings,et al. Epidemiology of Infant Dengue Cases Illuminates Serotype-Specificity in the Interaction between Immunity and Disease, and Changes in Transmission Dynamics , 2015, PLoS neglected tropical diseases.
[78] Cameron P Simmons,et al. A new class of highly potent, broadly neutralizing antibodies isolated from viremic patients infected with dengue virus , 2014, Nature Immunology.
[79] S. Mahmood,et al. Association of FcγRIIa Polymorphism with Clinical Outcome of Dengue Infection: First Insight from Pakistan. , 2015, The American journal of tropical medicine and hygiene.
[80] J. Knowles,et al. Tools for Analyzing Mixed Effect Regression Models , 2015 .
[81] E. Harris,et al. Cryo-EM structure of an antibody that neutralizes dengue virus type 2 by locking E protein dimers , 2015, Science.
[82] A. Burlingame,et al. Erratum: The ubiquitin-modifying enzyme A20 restricts ubiquitination of the kinase RIPK3 and protects cells from necroptosis , 2015, Nature Immunology.
[83] Andreas Handel,et al. Crossing the scale from within-host infection dynamics to between-host transmission fitness: a discussion of current assumptions and knowledge , 2015, Philosophical Transactions of the Royal Society B: Biological Sciences.
[84] Corrigendum: A new class of highly potent, broadly neutralizing antibodies isolated from viremic patients infected with dengue virus , 2015, Nature Immunology.
[85] Jacques-François Thisse,et al. The state of the art and a research agenda , 2015 .
[86] Eva Harris,et al. Dengue virus NS1 triggers endothelial permeability and vascular leak that is prevented by NS1 vaccination , 2015, Science Translational Medicine.
[87] Nicholas Jackson,et al. Efficacy and Long-Term Safety of a Dengue Vaccine in Regions of Endemic Disease. , 2015, The New England journal of medicine.
[88] P. Desprès,et al. Recognition determinants of broadly neutralizing human antibodies against dengue viruses , 2015, Nature.
[89] Anavaj Sakuntabhai,et al. Asymptomatic humans transmit dengue virus to mosquitoes , 2015, Proceedings of the National Academy of Sciences.
[90] Bivariate Linear Errors-In-Variables Estimation , 2015 .
[91] V. Kostyuchenko,et al. A highly potent human antibody neutralizes dengue virus serotype 3 by binding across three surface proteins , 2015, Nature Communications.
[92] Judith M. Fonville,et al. Dengue viruses cluster antigenically but not as discrete serotypes , 2015, Science.
[93] B. Althouse,et al. The tortoise or the hare? Impacts of within-host dynamics on transmission success of arthropod-borne viruses , 2015, Philosophical Transactions of the Royal Society B: Biological Sciences.
[94] E. Harris,et al. Homotypic Dengue Virus Reinfections in Nicaraguan Children. , 2016, The Journal of infectious diseases.
[95] Katia Koelle,et al. Drivers of Inter-individual Variation in Dengue Viral Load Dynamics , 2016, PLoS Comput. Biol..
[96] Malaya K. Sahoo,et al. Viremia and Clinical Presentation in Nicaraguan Patients Infected With Zika Virus, Chikungunya Virus, and Dengue Virus , 2016, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[97] Cameron P. Simmons,et al. Modelling Virus and Antibody Dynamics during Dengue Virus Infection Suggests a Role for Antibody in Virus Clearance , 2016, PLoS Comput. Biol..
[98] Daniel J. Laydon,et al. Benefits and risks of the Sanofi-Pasteur dengue vaccine: Modeling optimal deployment , 2016, Science.
[99] A. Nisalak,et al. Incidence of Dengue Virus Infection in Adults and Children in a Prospective Longitudinal Cohort in the Philippines , 2016, PLoS neglected tropical diseases.
[100] E. Harris,et al. Neutralizing antibody titers against dengue virus correlate with protection from symptomatic infection in a longitudinal cohort , 2016, Proceedings of the National Academy of Sciences.
[101] K. Bleakley,et al. Increased adaptive immune responses and proper feedback regulation protect against clinical dengue , 2017, Science Translational Medicine.
[102] J. Taubenberger,et al. IgG antibodies to dengue enhanced for FcγRIIIA binding determine disease severity , 2017, Science.
[103] E. Harris,et al. Immune correlates of protection for dengue: State of the art and research agenda. , 2017, Vaccine.
[104] F. Rovida,et al. Antibody-based assay discriminates Zika virus infection from other flaviviruses , 2017, Proceedings of the National Academy of Sciences.